These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038 [TBL] [Abstract][Full Text] [Related]
25. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694 [TBL] [Abstract][Full Text] [Related]
26. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Wiltshaw E; Kroner T Cancer Treat Rep; 1976 Jan; 60(1):55-60. PubMed ID: 1000519 [TBL] [Abstract][Full Text] [Related]
27. Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747 [TBL] [Abstract][Full Text] [Related]
28. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987 [TBL] [Abstract][Full Text] [Related]
29. Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously. Jodrell DI; Bowman A; Stewart M; Dunlop N; French R; MacLellan A; Cummings J; Smyth JF Br J Cancer; 1998 Mar; 77(5):808-11. PubMed ID: 9514062 [TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967 [TBL] [Abstract][Full Text] [Related]
31. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139 [TBL] [Abstract][Full Text] [Related]
32. [A phase I study of DWA2114R]. Ariyoshi Y; Wakui A; Hasegawa K; Niitani H; Ogawa M; Sakai Y; Majima H; Furue H; Miyake H; Taguchi T Gan To Kagaku Ryoho; 1992 May; 19(5):685-93. PubMed ID: 1580642 [TBL] [Abstract][Full Text] [Related]
33. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343 [TBL] [Abstract][Full Text] [Related]
34. CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs. Beijnen JH; Flora KP; Halbert GW; Henrar RE; Slack JA Br J Cancer; 1995 Jul; 72(1):210-8. PubMed ID: 7599054 [TBL] [Abstract][Full Text] [Related]
35. Phase I trial of dihydroxyanthracenedione. Van Echo DA; Whitacre MY; Aisner J; Wiernik PH Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015 [TBL] [Abstract][Full Text] [Related]
36. Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Catimel G; Coquard R; Guastalla JP; Merrouche Y; Le Bail N; Alakl MK; Dumortier A; Foy M; Clavel M Cancer Chemother Pharmacol; 1995; 35(3):246-8. PubMed ID: 7805184 [TBL] [Abstract][Full Text] [Related]
37. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747 [TBL] [Abstract][Full Text] [Related]
38. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK; Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532 [TBL] [Abstract][Full Text] [Related]
39. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921 [TBL] [Abstract][Full Text] [Related]
40. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. Brown TD; Ettinger DS; Donehower RC J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]